

 ITEL
 : 022 - 3001 5666
 : 022 - 2405 7708

 FAX
 : 022 - 2405 7708
 : 022 - 2405 7708

 E-Mail
 : info@naxparlab.com
 : 022 - 2405 7708

 Visit us at: www.naxparlab.com
 : 022 - 2405 7708
 : 022 - 2405 7708

 Image: CIN No.
 : 136912MH19B2PLC027925
 : 022 - 2405 7708

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLOG. NO. 8, JOGANI IND. COMPLEX, SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

Date: 30th May 2016

To, Department of Corporate Service (DCS-CRD), BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400001

Sub: <u>Submission of Audited Standalone and consolidated Financial Results for fourth</u> <u>quarter and year ended 31<sup>x</sup> March. 2016 in pursuance of regulation 33 of Listing</u> <u>Obligation and Disclosure Requirement. 2015.</u>

Ref.: Parnax Lab Limited . Script Code- 506128

Dear Sir,

Kindly find enclosed herewith the following :

- 1. A Copy of Audited Standalone and consolidated Financial results of the Company for the Financial year ended March 31,2016,
- 2. Auditor's Report on standalone and consolidated Financial Results of the company for the Financial year ended March 31,2016.
  - 3. Form-A for the standalone and consolidated Financial Result of the company •

Kindly take on record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

For PARNAX LAB LIMITED



PRAKASH SHAH WHOLE TIME DIRECTOR & CEO DIN NO -00440980





#### DECLARATION

Pursuant to the amendments made by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment)Regulations,2016 dated 25<sup>th</sup> May 2016 having effect from 1<sup>st</sup> April 2016 we hereby declare that the Standalone and Consolidated audit report so provided by the auditors of the company for the financial year ended 31<sup>st</sup> March 2016 is unmodified.

For Parnax Lab Ltd,

Mr. Prakash Shah Director Cum CFO DIN: 00440980

Place: Mumbai Date:30th May 2016.



	GALA NO. 114, BLDG. NO. 8,JOG	PARNAX LAB LI		ABHATTI, MUMBAI 40		
	Tel : 022 - 3001 5666, Fax : 2405	the second s				· · · ·
		CIN:-L36912MH1982P	the second se			
	STATEMENT OF STANDALONE FINANCIAL	RESULTS FOR TH	E FOURTH QU	JARTER AND YEA	R ENDED 31.03.2	
		Audited	Unaudited	Audited	Audited	Rs. In La Audited
	Particulars	Current Quarter	Previous	Corresponding	Current Year	Previous
	Fatuculais	Ended	Quarter	Quarter Ended	Ended	Year
		31.03.2016	ended	31.03.2015	31.03.2016	31.03.2015
		51.05.2010	31.12.2015	51.05.2015	51.05.2010	51.05.2015
-	lassans from on castions		01.12.2010			
1	Income from operations	01.10	446.94	207 70	722.04	4 505 51
	(a) Net sales/income from operations	81.19	116.21	387.78	722.84	1,585.55
	(Net of excise duty)					
	(b) Other operating income	48.72	2.63	45.31	66.15	77.50
	Total income from operations (net)	129.91	118.84	433.09	788.99	1,663.13
100		· · · · · · · · · · · · · · · · · · ·				•
2	Expenses	12.22	22.04	112.74	245.00	
	(a) Cost of materials consumed	13.32	32.81	142.74	316.89	722.4
	(b) Purchases of stock-in-trade	10.33	8.12	99.53	69.36	153.5
	(c) Changes in inventories of finished goods,	0.29	-	(6.63)	25.08	155.2
	work-in-progress and stock-in-trade					4 1000
	(d) Employee benefits expense	47.46	* 31.08	68.96	134.70	284.3
	(e) Depreciation and amortisation expense	15.99	14.52	21.03	59.51	79.8
	(f) Other expenses (Any item exceeding 10%	58.90	39.19	84.89	217.55	301.6
	of the total expenses relating to continuing					
	operations to be shown separately)					
	Total expenses	146.29	125.72	410.52	823.09	1,697.0
3	Profit / (Loss) from operations before other	(16.38)	(6.88)	22.57	(34.10)	(33.9
	income, finance costs and exceptional					
	items(1-2)					
4	Other Income	100	· · ·	-		
		1000				
5	Profit / (Loss) from ordinary activities	10				
	before finance costs and exceptional items	(16.38)	(6.88)	22.57	(34.10)	(33.9
	(3 ± 4)					s
6	Finance costs	25.18	24.85	37.19	108.54	141.4
7	Profit / (Loss) from ordinary activities after	(41.56)	(31.73)	(14.62)	(142.64)	(175.4
	finance costs but before exceptional items					
	(5 ± 6)	a state of the second				
8	Exceptional Items				· · · · · · · · · · · · · · · · · · ·	
9	Profit / (Loss) from ordinary activities	(41.56)	(31.73)	(14.62)	(142.64)	(175.4
	before tax (7 ± 8)					
10	Tax Expense	-	-	-	(41.15)	(55.6
11	Net Profit / (Loss) from ordinary activities	(41.56)	(31.73)	(14.62)	(101.49)	(119.7
	after tax (9 ± 10)					
12	Extraordinary items (net of tax expense Rs	-			•	-
	Lakhs)	· · · · · · · · · · · · · · · · · · ·				
13	Net Profit / (Loss) for the period (11 ± 12)	(41.56)	(31.73)	(14.62)	(101.49)	(119.7
	and the second se					
14	Share of Profit / (loss) of associates*			100 AND 100	-	
				and the second		
15	Minority Interest *	· · · ·				1 <u>.</u> .
16	Net Profit / (Loss) after taxes, Minority	(41.56)	(31.73)	(14.62)	(101.49)	(119.7
	interest and share of profit / (loss) of	(,	()	(=	(101.15)	(115.7
	associates $(13 \pm 14 \pm 15)$ *					
-Se Lago		-		1.00		
17	Paid-up equity share capital	850.4866	* 850.4866	850.4866	850.4866	850.48
	(Face Value of the share Rs. 10)	000.4000	000.4000	0.000	050.4000	050.48
18	Reserve excluding Revaluation Reserves as	•10 ×	Contractor of the local data	and the second	411.51	652.7
	per balance sheet of previous accounting year				411.51	052.7
	Final and the short of providuo accounting year		AX I			
		The second s	IA			CONTRACTOR AND INCOME.

Particulars	Audited Current Quarter Ended 31.03.2016	Unaudited Previous Quarter ended 31.12.2015	Audited Corresponding Quarter Ended 31.03.2015	Audited Current Year Ended 31.03.2016	Audited Previous Year 31.03.2015
(of Rs. 10/-each) (not annualised) (a) Basic (b) Diluted	(0.49) (0.49)	(0.37) (0.37)	A CONTRACTOR OF A CONTRACTOR O	(1.19) (1.19)	(1.41) (1.41)
Earning per share (after extraordinary items) (of Rs. 10/-each) (not annualised) (a) Basic (b) Diluted	(0.49) (0.49)	(0.37) (0.37)		, (1.19) (1.19)	(1.41) (1.41)

2 2

140

States of the sec

For Parnax Lab Director

### PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022. Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

.

						Rs. In La
		Audited	Unaudited	Audited	Audited	Audited
	Particulars	Current Quarter Ended 31.03.2016	Previous Quarter ended 31.12.2015	Corresponding Quarter Ended 31.03.2015	Current Year Ended 31.03.2016	Previous Year 31.03.2015
1	Income from operations					
	(a) Net sales/income from operations (Net of excise duty)	1,885.23	1,743.53	2598.15	7,118.23	10,274.6
	(b) Other operating income	48.37	3.91	48.90	70.32	81.4
	Total income from operations (net)	1,933.60	1,747.44	2,647.05	7,188.55	10,356.0
	Expenses					
	(a) Cost of materials consumed	1,032.86	857.58	1690.24	3,672.66	6,326.9
	(b) Purchases of stock-in-trade	(21.79)	8.12	99.53	37.24	153.
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	24.90	* 13.76	(47.73)	70.39	210.7
	(d) Employee benefits expense	217.51	195.76	191.00	746.05	771.7
	(e) Depreciation and amortisation expense	80.00	70.10	94.05	289.54	299.3
	<ul> <li>(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)</li> </ul>	472.14	417.58	395.14	1,595.12	1,609.9
	Total expenses	1805.62	1,562.90	2422.23	6,411.00	9,372.1
	Profit / (Loss) from operations before other income, finance costs and exceptional items(1-2)	127.98	184.54	224.82	777.55	983.9
	Other Income	-	-	-		-
	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	127.98	184.54	224.82	777.55	983.9
	Finance costs	101.78	99.82	115.12	429.39	439.7
ŕ	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	26.20	84.72	109.70	348.16	544.1
	Exceptional Items	-	-	-	4	-
	Profit / (Loss) from ordinary activities before tax (7 ± 8)	26.20	84.72	109.70	348.16	544.1
0	Tax Expense		-	-	97.40	118.4
1	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	26.20	84.72	109.70	250.76	425.7
2	Extraordinary items (net of tax expense Rs Lakhs)	-		•		-
3	Net Profit / (Loss) for the period (11 $\pm$ 12)	26.20	84.72	109.70	250.76	425.7
4	Share of Profit / (loss) of associates*	)ab	•	-	-	•
5	Minority Interest *	(0.12)	0.23	(0.10)	0.70	1.(
6	Net Profit / (Loss) after taxes, Minority	26.32	84.49	109.80	250.06	424.6

-		Audited	Unaudited -	Audited	Audited	Audited
	Particulars	Current Quarter Ended 31.03.2016	Previous Quarter ended 31.12.2015	Corresponding Quarter Ended 31.03.2015	Current Year Ended 31.03.2016	Previous Year 31.03.2015
17	Paid-up equity share capital (Face Value of the share Rs. 10 )	850.4866	850.4866	850.4866	850.4866	850.4866
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year			•	1,663.46	1,238.84
19.i	Earning per share (before extraordinary items) (of Rs. 10/-each) (not annualised)					
	(a) Basic	0.31	0.99	1.29	2.94	4.99
	(b) Diluted	0.31	0.99	1.29	2.94	4.99
19.ii	Earning per share (after extraordinary items)					
	(of Rs. 10/-each) (not annualised)		•			
	(a) Basic (b) Diluted	0.31	0.99	1.29	2.94	4.99
	(b) Diluted	0.31	0.99	1.29	2.94	4.99

For Parnax Lab Jug. Director

<ul> <li>The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 300, 2016</li> <li>The Comparity has opted to submit Standalone as well as Consolidiated financial statements. The Consolidated financial results</li> <li>Since there is no income.</li> <li>The figures provided above are from new line of business is. Pharmaceutical Activity. The figures provided above are from new line of business is. Pharmaceutical Activity.</li> <li>The figures practical Activity and net profit after tax from earlier activity, the figures provided above are from new line of business is. Pharmaceutical Activity.</li> <li>The figures practical Activity.</li> <li>The figures practical Activity.</li> <li>The Consolidated financial results are prepared in accordance, with Accounting Standards (AS 21 and 23) notified by Companies Accounting Standards Rules. 2006</li> <li>Elevens prepared in accordance, with Accounting Standards (AS 21 and 23) notified by Companies Accounting Standards Rules. 2006</li> <li>The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangments for its export business.</li> <li>The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangments for its export busines.</li> </ul>	<ul> <li>The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 30, 2000 moments that comparise the results of Parmax Lab Limited and One Subsidiary Company.</li> <li>The Comparise the results of Parmax Lab Limited and One Subsidiary Company.</li> <li>The Comparise the results of Parmax Lab Limited and net profit after tax from earlier activity, the figures provided above are from new line of comprises the treast of the mancentre. Activity and net profit after tax from earlier activity, the figures provided above are from new line of Sine Suppose of the last quarter is balancing figures between audited figures in respect to full financial year upto March 2016 and the unaddited published year to date figures upto Decomber 31, 2015 being the date of the end of third quarter of the financial year upto March 2016 and the unaddited published financial results are subject to full financial year upto March 2016 and the unaddited published financial results are subject to full financial results are subject to four date figures between audited published financial year upto March 2016 and the unaddited published financial results are subject to four date science.</li> <li>The Consolidated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies Accounting Standards Rules, 2006</li> <li>Figures prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies Accounting Standards fues, 2006</li> <li>Figures prepared financial results are accounted and the total public of the company has made alternate arrangment for its export business.</li> <li>B The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business.</li> <li>Date: 30.05 2016</li> <li>Date: 30.05 2016</li> <li>Place: Mumbai</li> </ul>	Notes:	
<ul> <li>2 The Company has opted to submit Standalone as well as Consolidated financial statements. The Consolidated financial results of periods: Lab Limited and One Subsidiary Company.</li> <li>3 Since there is no incomprise the results of Parnex Lab Limited and One Subsidiary Company.</li> <li>3 Since there is no incomprise the results of Parnex Lab Limited and One Subsidiary Company.</li> <li>4 The figures of the last quarter is balancing figures between audited figures in respect to full financial year upto March 2016 and the Unsinees is. Pharmaceutical Activity.</li> <li>5 The Consolidated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies Accounting Standards Rules. 2006</li> <li>5 The Consolidated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies Accounting Standards Rules. 2006</li> <li>6 Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.</li> <li>7 EPS for quarter is Galing into one segment : Dealing in Pharmaceutical Formulations</li> <li>9 The Company is dealing into one segment : Dealing in Pharmaceutical Formulations</li> <li>9 The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business</li> <li>9 The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business</li> </ul>	<ul> <li>2 The Company has optied to submit Standalone as well as Consolidated financial statements. The Consolidated financial results comprises the results of neuronie symontiture and net profit after tax from earlier activity, the figures provided above are from new line of business i.e. Pharmaceutical Activity.</li> <li>3 Since there is no income, expenditure and net profit after tax from earlier activity, the figures provided above are from new line of business i.e. Pharmaceutical Activity.</li> <li>4 The figures is no income, expenditure and net profit after tax from earlier activity, the figures provided above are from new line of business i.e. Pharmaceutical Activity.</li> <li>5 The Consolidated financial year upto December 31, 2015 being the date of the end of third quarter of the financial year which were subject to limited results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies 5 The Consolidated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies 6 Figures performs preview.</li> <li>6 Figures protous periodyear have been te-grouped, re-classified and restated wherever found necessary.</li> <li>7 PES for quarter ended is on non amualised basis.</li> <li>8 The Company is dealing into one segment 1. Dealing in Pharmaceutical Formulations.</li> <li>9 The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has declared basis.</li> <li>9 Date: 30.65.2016</li> <li>9 Date: 30.65.2016</li> <li>9 Date: Numbai</li> </ul>	above results have been reviewed by the 2016	y the Board of Directors at their meeting held on May
<ul> <li>3 Since there is no income, expenditure and net profit after tax from earlier activity, the figures provided above are from new line of business i.e. Pharmaceutical Activity.</li> <li>4 The figures of the figures to balancing figures between audited figures in respect to full financial year upto March 2016 and the unaudited published year to date figures between audited figures in respect to full financial year upto March 2016 and the unaudited published year to date figures upto December 31, 2015 being the date of the end of third quarter of the financial year which were subject to limited review.</li> <li>5 The Consolidated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies commendated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies</li> <li>6 Figures pertaining to previous periodyaen have been re-grouped, re-classified and restated wherever found necessary.</li> <li>7 EPS for quarter ended is on non annualised basis.</li> <li>8 The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business.</li> <li>9 The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment. Place: Mumbai</li> <li>9 The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment.</li> </ul>	<ul> <li>3 Since there is no income, expenditure and net profit after tax from earlier activity, the figures provided above are from new line of business ic Pharmaceutical Activity.</li> <li>4 The figures of the last quarter is balancing glues between audited figures in respect to full financial year upto March 2016 and the unaudited published year to date figures upto Decomber 31, 2015 being the date of the end of third quarter of the financial year which were subject to limited review.</li> <li>5 The Consolidated financial results are prepared in accordance with Accounting Standards KMS 21 and 23) notified by Companies Theoreouthing Standards Rules. 2006</li> <li>6 Figures pertaining to previous period/year have been ne-grouped, re-classified and resisted wherever found necessary.</li> <li>7 EPS for quarter ended is on non amualised basis.</li> <li>9 The Company is dealing into one segment : Dealing in Pharmaceutical Formulations</li> <li>9 The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business.</li> <li>9 The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business.</li> <li>9 The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment lear its export business.</li> </ul>	2 The Company has opted to submit Standalone as well as Consolidated financial comprise the results of Parnax Lab Limited and One Subsidiary Company	I statements. The Consolidated financial results
<ul> <li>4 The figures of the last quarter is balancing figures between audited figures in respect to full financial year upto March 2016 and the unaudited part to bublished year to date figures upto December 31, 2015 being the date of third quarter of the financial year which unaudited by Companies subject to limited review.</li> <li>5 The Consolicated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies Accounting Standards Rules. 2006</li> <li>6 Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.</li> <li>7 EPS for quarter ended is on non annualised basis.</li> <li>9 The Company is dealing into one segment : Dealing in Pharmaceutical Formulations</li> <li>9 The Company is dealined in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangmenti for its export business.</li> </ul> Date: 30.65.2016 Pare: Mumbai Pare: Mumbai For Parmax Lab Limited Place: Mumbai Pare: Mumbai Pare: Mumbai For Parmax Lab Limited Place: Mumbai Pare: Mumbai Pare: Mumbai Pare: Mumbai Pare: Mumbai Pare: Mumbai	<ul> <li>The figures of the last quarter is balancing figures between audited figures in respect to full financial year which unauded published year to date figures upto December 31, 2015 being the date of the end of third quarter of the financial year which unaudited published year to date figures upto December 31, 2015 being the date of the end of third quarter of the financial year which where subject to limited review.</li> <li>The Consolidated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies Accounting Standards Rules. 2006</li> <li>Egures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.</li> <li>TES for quarter ended is on non annualised basis.</li> <li>The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export busines.</li> </ul> Date: 30.05.2016 Pare: Mumbai For Parmax Lab Limited Flace. Mumbai The Company is declared layoff in its Silvassa plant due to labour unreast. However, the Company has declared layoff in the super superstance. Nower, the Company has made alternate arrangment for its export busines. Date: 30.05.2016 Pare: Mumbai For Parmax Lab Limited Flace. Mumbai Pare: Mumbai<	3 Since there is no income, expenditure and net profit after tax from earlier activity business i.e. Pharmaceutical Activity.	y, the figures provided above are from new line of
<ul> <li>Fine Consolidated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies Accounting Standards Rules, 2006</li> <li>Figures pertaining to previous periodyear have been re-grouped, re-classified and restated wherever found necessary.</li> <li>Fies for quarter ended is on non annualised basis.</li> <li>The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business</li> <li>Date: 30.05.2016</li> <li>Place: Mumbai</li> <li>For Parnax Lab Limited</li> <li>Mno</li> <li>Time Direct</li> </ul>	<ul> <li>Fine Consolidated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies Accounting Standards Rules, 2006</li> <li>Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.</li> <li>Fise Stor quarter ended is on non annual basis.</li> <li>The Company is dealing into one segment : Dealing in Pharmaceutical Formulations</li> <li>The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business</li> <li>Date: 30.05.2016</li> <li>Place: Mumbai</li> <li>For Parnax Lab Limited</li> <li>Mh</li> </ul>	4 The figures of the last quarter is balancing figures between audited figures in res unaudited published year to date figures upto December 31, 2015 being the date were subject to limited review.	spect to full financial year upto March 2016 and the e of the end of third quarter of the financial year which
6 Figures perialining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.         7 EPS for quarter ended is on non amualised basis.         8 The Company is dealing into one segment : Dealing in Pharmaceutical Formulations for its export business         9 The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business         Date: 30.05.2016         Place: Mumbai	6       Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.         7       EPS for quarter ended is on non amualised basis.         8       The Company is dealing into one segment : Dealing in Pharmaceutical Formulations         9       The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business         Date: 30.05.2016       Place: Mumbai         Place: Mumbai       For Parmax Lab Limited	<sup>5</sup> The Consolidated financial results are prepared in accordance with Accounting S Accounting Standards Rules, 2006	Standards (AS 21 and 23) notified by Companies
7       FPS for quarter ended is on non annualised basis.         8       The Company is dealing into one segment : Dealing in Pharmaceutical Formulations         9       The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business         Date: 30.05.2016       Place: Mumbai         Place: Mumbai       For Parmax Lab Limited         Min       Place: Mumbai	7       FPS for quarter ended is on non annualised basis.         8       The Company is dealing into one segment : Dealing in Pharmaceutical Formulations         9       The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business         Date: 30.05.2016       Date: 30.05.2016         Place: Mumbai       For Parmax Lab Limited Place: Mumbai	6 Figures pertaining to previous period/year have been re-grouped, re-classified ar	ind restated wherever found necessary.
8       The Company is dealing into one segment : Dealing in Pharmaceutical Formulations         9       The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangmentific its export business         Date: 30.05.2016       For Parmax Lab Limited         Place: Mumbai       For Parmax Lab Limited         Mhc       Mineral         Time Direct       Time Direct	8       The Company is dealing into one segment : Dealing in Pharmaceutical Formulations         9       The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business         Date: 30.05.2016       For Parmax Lab Limited         Place: Mumbai       Min         Time Director       Min	7 EPS for quarter ended is on non annualised basis.	
<ul> <li>Ine Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangmentic for its export business</li> <li>Date: 30.05.2016</li> <li>Place: Mumbai</li> <li>Mine Direct</li> </ul>	9 The Company has declared layoff in its Silvassa plant due to labour unreast. However, the Company has made alternate arrangment for its export business Date: 30.05.2016 Place: Mumbai Place: Mumbai	8 The Company is dealing into one segment : Dealing in Pharmaceutical Formulation	tions
		9 The Company has declared layoff in its Silvassa plant due to labour unreast. Hov for its export business	wever, the Company has made alternate arrangment
		Date:30.05.2016	For Parnax Lab Limited
NEUMBAN (NEUMARAN)	MUMBAI X	Place: Mumbai	A A
MINNBAI *	MUMBAI V		No. 1
			MUMBAI
			<u> </u>

### PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022. Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com CIN:-L36912MH1982PLC027925

# Statement Standalone of Assets and Liabilities as at March 31, 2016

		<u> </u>	(Rs. in Lacs
		Year End	
A	EQUITY AND LIABILITIES	31.03.2016	31.03.2015
1		The second	
	Shareholders' funds		
(a)	Share capital	850.49	850.49
(b)	Reserves and surplus	310.02	411.51
(c)	Money received against share warrants	-	an a
•	Sub-total - Shareholders' funds	1,160.51	1,262.00
2	Share application money pending allotment		- AND 26 (F.
3	Minority interest*	-	
4	Non-current liabilities		
(a)	Long-term borrowings	1,257.57	1,537.83
(b)	Deferred tax liabilities (net)		
(c)	Other long-term liabilities	-	
(d)	Long-term provisions		
_	Sub-total - Non-current liabilities	1,257.57	1,537.83
5	Current liabilities		
(a)	Short-term borrowings	200.76	204.86
(b)	Trade Payables	36.97	205.97
(c)	Other current liabilities	339.52	297.95
(d)	Short-term provisions	30.55	7.86
	Sub-total - Current liabilities	607.80	716.64
-	TOTAL - EQUITY AND LIABILITIES	3,025.88	3,516.47
B	ASSETS		
1	Non-current assets		
(a)	Fixed assets	668.66	728.04
(b)	Goodwill on consolidation *	-	
(c)	Non-current investments	1,071.44	1,071.44
(d)	Deferred tax assets (net)	254.15	202.87
(e)	Long-term loans and advances	9.71	16.72
(f)	Other non-current asstes	- A MARKEN	0.53
	Sub-total - Non-current Assets	2,003.96	2,019.60
2	Current assets		
(a)	Current Investments	enterio -	
(b)	Inventories	31.81	143.43
(c)	Trade receivables	746.75	1,083.88
(d)	Cash and cash equivalents	17.07	37.13
	Short-term loans and advances	226.29	232.43
(f)	Other current asstes	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1.100 28.1
	Sub-total - Current Assets	1,021.92	1,496.87
	TOTAL - ASSETS	3,025.88	3,516.47

\*Applicable in the case of consolidated statement of asets and liabilities

For Parnax Lab Limited

Prakash M Shah

(Whole Time Director)

A MUNBAL

Mumbai Date : 30-05-2016

### PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022. Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com CIN:-L36912MH1982PLC027925

# Statement of Consolidated Assets and Liabilities as at March 31, 2016

Section.		(Rs. in La Year Ended As At		
		31.03.2016	ad As At 31.03.2015	
A	EQUITY AND LIABILITIES	01.00.2010	51.05.2015	
1	Shareholders' funds			
(a)	Share capital	850.49	950.40	
(b)	Reserves and surplus	1,913.52	850.49	
(c)	Money received against share warrants	1,913.32	1,663.46	
	Sub-total - Shareholders' funds	2,764.01	2,513.95	
2	Share application money pending allotment	2,704.01	2,513.95	
3	Minority interest*	5.48	1 70	
4	Non-current liabilities	0.40	4.78	
(a)	Long-term borrowings	2,231.82	2 562 04	
(b)	Deferred tax liabilities (net)	48.71	2,562.94 84.68	
(C)	Other long-term liabilities		04.00	
(d)	Long-term provisions		- 13.98	
	Sub-total - Non-current liabilities	2,280.53	2,661.60	
5	Current liabilities	2,200.00	2,001.00	
(a)	Short-term borrowings	1,304.96	1 000 47	
(b)	Trade Payables	308.82	1,209.17	
(C)	Other current liabilities	1,127.09	927.08	
(d)	Short-term provisions	149.52	805.83	
	Sub-total - Current liabilities	2,890.39	159.41	
	TOTAL - EQUITY AND LIABILITIES	7,940.41	3,101.49	
В	ASSETS	7,940.41	8,281.82	
1	Non-current assets			
(a)	Fixed assets	1000.04		
(b)	Goodwill on consolidation *	4,028.64	3,705.19	
(c)	Non-current investments	90.95	-	
(d)	Deferred tax assets (net)	90.95	85.95	
(e)	Long-term loans and advances	764.25	693.91	
(f)	Other non-current asstes	704.25	0.52	
	Sub-total - Non-current Assets	4,883.84	4,485.57	
2	Current assets	1,000.04	4,405.57	
(a)	Current Investments			
(b)	Inventories	662.85	702.40	
(c)	Trade receivables	1,941.77	703.19	
(d)	Cash and cash equivalents	38.40	2,350.12	
(e)	Short-term loans and advances	413.55	235.90	
(f)	Other current asstes	413.00	507.04	
	Sub-total - Current Assets	3,056.57	2 700 05	
	TOTAL - ASSETS	7,940.41	3,796.25 8,281.82	

\*Applicable in the case of consolidated statement of asets and liabilities

Mumbai Date : 30-05-2016

1257





Prakash M Shah (Whole Time Director)

CHARTERED ACCOUNTANTS

#### Auditor's Report on Quarterly Consolidated Financial Results and Consolidated Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

#### То

#### Board of Director of Parnax Lab Limited,

We have audited the quarterly consolidated financial results of **Parnax Lab Limited** for the quarter ended 31<sup>st</sup> March 2016 and the Consolidated year to date results for the period 1<sup>st</sup> April 2015 to 31<sup>st</sup> March 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These consolidated quarterly financial results as well as consolidated year to date financial results have been prepared from consolidated interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated interim financial statement, which have been prepared in accordance with the recognition and measurement principal laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), mandated under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us, these consolidated quarterly financial results as well as the consolidated year to date results:

- (i) include the quarterly financial results and year to date financial result of the following entries:
  - a) Parnax Lab Limited (Holding Company); and
  - b) Naxpar Pharma Private Limited (Subsidiary Company);



ADHA SINGHAL & ASSOCIATES

CHARTERED ACCOUNTANTS

- (ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (iii) give a true and fair view of the consolidated net profit and other financial information for the quarter ended 31<sup>st</sup> March 2016 as well as the consolidated year to date result for the period from 1<sup>st</sup> April 2015 to 31<sup>st</sup> March 2016.

Further, we report that the figures for the quarter ended 31<sup>st</sup> March, 2016 represents the derived figures between the audited figures in respect of current full financial year ended 31<sup>st</sup> March, 2016 and the published unaudited year to date figures up to 31<sup>st</sup> December, 2015, being the date of the end of the third quarter of the financial year, which were subjected to a limited review as stated above.

#### For Ladha Singhal and Associates

Chartered Accountants (FRN: 120241W)

Vivodlaghe

(Vinod Ladha) Partner M. No. 104151

Place: - Mumbai Dated: - 30<sup>th</sup> May 2016



#### CHARTERED ACCOUNTANTS

#### Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

#### To

#### Board of Director of Parnax Lab Limited,

We have audited the quarterly financial results of **Parnax Lab Limited** for the quarter ended 31<sup>st</sup> March 2016 and the year to date results for the period 1<sup>st</sup> April 2015 to 31<sup>st</sup> March 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as year to date financial results have been prepared on the basis of interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principal laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31<sup>st</sup> March 2016 as well as the year to date result for the period from 1<sup>st</sup> April 2015 to 31<sup>st</sup> March 2016.

Further, we report that the figures for the quarter ended 31<sup>st</sup> March, 2016 represents the derived figures between the audited figures in respect of current full financial year ended 31<sup>st</sup> March, 2016 and the published unaudited year to date figures up to 31<sup>st</sup> December, 2015, being the date of the end of the third quarter of the financial year, which were subjected to a limited review as stated above.

For Ladha Singhal and Associates

Chartered Accountants (FRN: 120241W)

(Vinod Ladha) Partner M. No. 104151 Place: - Mumbai Dated: - 30<sup>th</sup> May 2016





Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX, SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

TEL. : 022 - 3001 5666
 FAX : 022 - 2405 7708
 E-Mail : info@naxparlab.com
 Visit us at: www.naxparlab.com
 CIN No. : L36912MH1982PLC027925

## Form A along with the Audited Standalone Financial Results

## Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations 2015

1.	Name of the Company	Parnax Lab Limited	
2.	Annual Financial Statements for the year ended	31 <sup>st</sup> March 2016	
3.	Type of Audit observation	Unmodified	
4.	Frequency of Observation	Not Applicable	

## Statement on Impact of Audit Qualification

For Parnax Lab Lim	lited	Chartere	<b>a Singhal &amp; Associates d Accountants</b> gistration No.: 120241W f	] .
∞ WWW Mr. Vindyak Desai Audit Committee Chairman	Mr. Prakash Shah CEO & Whole Time Director	B.M. × Mr. Baiju Shah CFO & Whole Time Director	For LADHA SINGHAL & AS CHARTERED ACCO Winod Ladha Partner Membership No.: 104451	SOCIATE: UNTANT: Partne

Date: 30th May 2016.